A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 6, 2011, Pages 2372-2382

  López Andrés, Natalia ^a   Martin Fernandez, Beatriz ^b   Rossignol, Patrick ^a   Zannad, Faiez ^a   Lahera, Vicente ^b   Fortuno, Maria Antonia ^c   Cachofeiro, Victoria ^b   Díez, Javier ^c,d  

^a INSERM   (France)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Fibrosis; Inflammation; Left ventricular hypertrophy

Indexed keywords

ALDOSTERONE; CARDIOTROPHIN 1; COLLAGEN; MINERALOCORTICOID; SODIUM; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; HYPERTENSION; MYOCARDIAL DISEASE; MYOCARDIAL REMODELING; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HEART RATE; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SODIUM CHLORIDE, DIETARY; SPIRONOLACTONE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 82855181170     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00283.2011     Document Type: Article

References (37)

1. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 25: 299-306, 2000.
2. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120: 893-901, 1992.
3. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26: 233-240, 1995.
4. Delcayre C, Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E, Swynghedauw B, Robert V. Cardiac aldosterone production and ventricular remodeling. Kidney Int 57: 1346-1351, 2000.
5. Freed DH, Borowiec AM, Angelovska T, Dixon IM. Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways. Cardiovasc Res 60: 365-375, 2003.
6. Habibi J, DeMarco VG, Ma L, Pulakat L, Rainey WE, Whaley- Connell AT, Sowers JR. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 300: H1484-H1491, 2011.
7. Handtrack C, Cordasic N, Klanke B, Veelken R, Hilgers KF. Effect of the angiotensinogen genotype on experimental hypertension in mice. J Mol Med 85: 343-350, 2007.
8. Lijnen P, Petrov V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol 21: 215-227, 1999.
9. Lopez-Andres N, Fortuno MA, Diez J, Zannad F, Lacolley P, Rossignol P. Vascular effects of cardiotrophin-1: a role in hypertension? J Hypertens 28: 1261-1272, 2010.
10. Lopez-Andres N, Inigo C, Gallego I, Diez J, Fortuno MA. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology 149: 4970-4978, 2008.
11. Lopez B, Gonzalez A, Lasarte JJ, Sarobe P, Borras F, Diaz A, Barba J, Tomas L, Lozano E, Serrano M, Varo N, Beloqui O, Fortuno MA, Diez J. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 23: 625-632, 2005.
12. Lopez B, Gonzalez A, Querejeta R, Barba J, Diez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens 27: 418-424, 2009.
13. Lopez N, Diez J, Fortuno MA. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine 30: 282-292, 2005.
14. Lopez N, Diez J, Fortuno MA. Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol 41: 902-913, 2006.
15. Martin-Fernandez B, de las Heras N, Miana M, Ballesteros S, Delgado C, Song S, Hintze T, Cachofeiro V, Lahera V. Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. J Cardiovasc Pharmacol 57: 114-121, 2010.
16. Martin-Fernandez B, Miana M, De Las Heras N, Ruiz-Hurtado G, Fernandez-Velasco M, Bas M, Ballesteros S, Lahera V, Cachofeiro V, Delgado C. Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat. Exp Physiol 94: 675-683, 2009.
17. Nakamura T, Kataoka K, Fukuda M, Nako H, Tokutomi Y, Dong YF, Ichijo H, Ogawa H, Kim-Mitsuyama S. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 54: 544-551, 2009.
18. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, Delcayre C, Lacolley P. Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst 7: 31-39, 2006.
19. Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 68: 109-117, 2005.
20. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE. Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 37: 794-800, 2001.
21. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR, et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 92: 1142-1146, 1995.
22. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
23. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 40: 23-27, 2002.
24. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27: 1039-1045, 1996.
25. Shahbaz AU, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, McGee JE, Weber KT. Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J Hypertens 28, Suppl 1: S25-S32, 2010.
26. Sontia B, Montezano AC, Paravicini T, Tabet F, Touyz RM. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. Hypertension 51: 915-921, 2008.
27. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61: 663-670, 2004.
28. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosteroneinduced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773-1781, 2002.
29. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262, 1999.
30. Thomas M, Vidal A, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. Am J Physiol Heart Circ Physiol 293: H2361-H2366, 2007.
31. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC Jr. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res 90: 128-134, 2002.
32. Wang Q, Clement S, Gabbiani G, Horisberger JD, Burnier M, Rossier BC, Hummler E. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol 286: F1178-F1184, 2004.
33. Yang T, Huang YG, Ye W, Hansen P, Schnermann JB, Briggs JP. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am J Physiol Renal Physiol 288: F1125-F1132, 2005.
34. Yoshida K, Kim-Mitsuyama S, Wake R, Izumiya Y, Izumi Y, Yukimura T, Ueda M, Yoshiyama M, Iwao H. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 28: 447-455, 2005.
35. Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 17: 174-180, 2008.
36. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 12: 617-622, 2010.
37. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11-21, 2011.